Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

Francis J. Giles; Eric J. Feldman; Gail J. Roboz; Richard A. Larson; Steven W. Mamus; Jorge E. Cortes; Srdan Verstovsek; Stefan Faderl; Moshe Talpaz; Miloslav Beran; Maher Albitar; Susan M. O'Brien; Hagop M. Kantarjian

doi:10.1016/S0145-2126(03)00094-8

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

Francis J. Giles, Eric J. Feldman, Gail J. Roboz, Richard A. Larson, Steven W. Mamus, Jorge E. Cortes, Srdan Verstovsek, Stefan Faderl, Moshe Talpaz, Miloslav Beran, Maher Albitar, Susan M. O'Brien, Hagop M. Kantarjian

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

A phase II study of troxacitabine, a non-natural dioxolane nucleoside L-enantiomer, was conducted in patients with chronic myelogenous leukemia in blastic phase (CML-BP). Patients were untreated for BP, or treated with imatinib mesylate (IM) as sole prior therapy for BP. Troxacitabine was given as an intravenous infusion over 30min daily for 5 days at a dose of 8.0mg/m² per day. Thirty-one patients, 29 (93%) of whom had failed prior IM therapy, received 51 courses of therapy. Grade 3 or 4 toxicities included stomatitis (4%), hand-foot syndrome (18%), and skin rash (12%). Four patients (13%) responded. Troxacitabine-based combinations merit study in IM-resistant CML.

Original language	English (US)
Pages (from-to)	1091-1096
Number of pages	6
Journal	Leukemia Research
Volume	27
Issue number	12
DOIs	https://doi.org/10.1016/S0145-2126(03)00094-8
State	Published - Dec 1 2003
Externally published	Yes

Keywords

Blast phase
Chronic myelogenous leukemia
Imatinib mesylate
Troxacitabine

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0145-2126(03)00094-8

Cite this

Giles, F. J., Feldman, E. J., Roboz, G. J., Larson, R. A., Mamus, S. W., Cortes, J. E., Verstovsek, S., Faderl, S., Talpaz, M., Beran, M., Albitar, M., O'Brien, S. M., & Kantarjian, H. M. (2003). Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leukemia Research, 27(12), 1091-1096. https://doi.org/10.1016/S0145-2126(03)00094-8

Giles, FJ, Feldman, EJ, Roboz, GJ, Larson, RA, Mamus, SW, Cortes, JE, Verstovsek, S, Faderl, S, Talpaz, M, Beran, M, Albitar, M, O'Brien, SM & Kantarjian, HM 2003, 'Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase', Leukemia Research, vol. 27, no. 12, pp. 1091-1096. https://doi.org/10.1016/S0145-2126(03)00094-8

@article{f68551a70eea4366b5f7a49edd7f676e,

title = "Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase",

abstract = "A phase II study of troxacitabine, a non-natural dioxolane nucleoside L-enantiomer, was conducted in patients with chronic myelogenous leukemia in blastic phase (CML-BP). Patients were untreated for BP, or treated with imatinib mesylate (IM) as sole prior therapy for BP. Troxacitabine was given as an intravenous infusion over 30min daily for 5 days at a dose of 8.0mg/m2 per day. Thirty-one patients, 29 (93%) of whom had failed prior IM therapy, received 51 courses of therapy. Grade 3 or 4 toxicities included stomatitis (4%), hand-foot syndrome (18%), and skin rash (12%). Four patients (13%) responded. Troxacitabine-based combinations merit study in IM-resistant CML.",

keywords = "Blast phase, Chronic myelogenous leukemia, Imatinib mesylate, Troxacitabine",

author = "Giles, {Francis J.} and Feldman, {Eric J.} and Roboz, {Gail J.} and Larson, {Richard A.} and Mamus, {Steven W.} and Cortes, {Jorge E.} and Srdan Verstovsek and Stefan Faderl and Moshe Talpaz and Miloslav Beran and Maher Albitar and O'Brien, {Susan M.} and Kantarjian, {Hagop M.}",

year = "2003",

month = dec,

day = "1",

doi = "10.1016/S0145-2126(03)00094-8",

language = "English (US)",

volume = "27",

pages = "1091--1096",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "12",

}

TY - JOUR

T1 - Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

AU - Giles, Francis J.

AU - Feldman, Eric J.

AU - Roboz, Gail J.

AU - Larson, Richard A.

AU - Mamus, Steven W.

AU - Cortes, Jorge E.

AU - Verstovsek, Srdan

AU - Faderl, Stefan

AU - Talpaz, Moshe

AU - Beran, Miloslav

AU - Albitar, Maher

AU - O'Brien, Susan M.

AU - Kantarjian, Hagop M.

PY - 2003/12/1

Y1 - 2003/12/1

N2 - A phase II study of troxacitabine, a non-natural dioxolane nucleoside L-enantiomer, was conducted in patients with chronic myelogenous leukemia in blastic phase (CML-BP). Patients were untreated for BP, or treated with imatinib mesylate (IM) as sole prior therapy for BP. Troxacitabine was given as an intravenous infusion over 30min daily for 5 days at a dose of 8.0mg/m2 per day. Thirty-one patients, 29 (93%) of whom had failed prior IM therapy, received 51 courses of therapy. Grade 3 or 4 toxicities included stomatitis (4%), hand-foot syndrome (18%), and skin rash (12%). Four patients (13%) responded. Troxacitabine-based combinations merit study in IM-resistant CML.

AB - A phase II study of troxacitabine, a non-natural dioxolane nucleoside L-enantiomer, was conducted in patients with chronic myelogenous leukemia in blastic phase (CML-BP). Patients were untreated for BP, or treated with imatinib mesylate (IM) as sole prior therapy for BP. Troxacitabine was given as an intravenous infusion over 30min daily for 5 days at a dose of 8.0mg/m2 per day. Thirty-one patients, 29 (93%) of whom had failed prior IM therapy, received 51 courses of therapy. Grade 3 or 4 toxicities included stomatitis (4%), hand-foot syndrome (18%), and skin rash (12%). Four patients (13%) responded. Troxacitabine-based combinations merit study in IM-resistant CML.

KW - Blast phase

KW - Chronic myelogenous leukemia

KW - Imatinib mesylate

KW - Troxacitabine

UR - http://www.scopus.com/inward/record.url?scp=10744228148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744228148&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(03)00094-8

DO - 10.1016/S0145-2126(03)00094-8

M3 - Article

C2 - 12921945

AN - SCOPUS:10744228148

SN - 0145-2126

VL - 27

SP - 1091

EP - 1096

JO - Leukemia Research

JF - Leukemia Research

IS - 12

ER -

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this